Search

Selective inhibitors of phosphoinositide 3-kinase delta are of interest for the treatment of inflammatory diseases. Initial optimization of a 3-substituted indazole hit compound targeting the kinase PIM1 focused on improving selectivity over GSK3β through consideration of differences in the ATP binding pockets. Continued kinase cross-screening showed PI3Kδ activity in a series of 4,6-disubstituted indazole compounds, and subsequent structure-activity relationship exploration led to the discovery of an indole-containing lead compound as a potent PI3Kδ inhibitor with selectivity over the other PI3K isoforms.

A new series of potent TG2 inhibitors are reported that employ a 4-aminopiperidine core bearing an acrylamide warhead. We establish the structure-activity relationship of this new series and report on the transglutaminase selectivity and in vitro ADME properties of selected compounds. We demonstrate that the compounds do not conjugate glutathione in an in vitro setting and have superior plasma stability over our previous series.

The SAR around a V1b antagonist HTS hit 3 was explored to produce a series of thiazole sulfonamides as a lead series with selectivity over the related V1 and oxytocin receptors.

Mechanistic studies reveal a low-energy palladacyclobutane intermediate that is energetically favored due to the relief of ring strain as a driving force.

The identification of a new series of RORc inverse agonists is described. Comprehensive structure-activity relationship studies of this reversed sulfonamide series identified potent RORc inverse agonists in biochemical and cellular assays which were also selective against a panel of nuclear receptors. Our work has contributed a compound that may serve as a useful in vitro tool to delineate the complex biological pathways involved in signalling through RORc. An X-ray co-crystal structure of an analogue with RORc has also provided useful insights into the binding interactions of the new series.

Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors. X-ray structures of a C-2 hydroxyethyl analogue in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the observed selectivity. Analysis of historical data from related molecules was used to develop a set of physicochemical compound design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability. This work culminated in the identification of a highly JAK1 selective compound (31) exhibiting favorable oral bioavailability across a range of preclinical species and robust efficacy in a rat CIA model.

A series of sulfonamide CCR2 antagonists was identified by high-throughput screening. Management of molecular weight and physical properties, in particular moderation of lipophilicity and study of pK(a), yielded highly potent CCR2 antagonists exhibiting good pharmacokinetic properties and improved potency in the presence of human plasma.

A new class of selective MMP-12 inhibitors have been identified via high throughput screening. Crystallization with MMP-12 confirmed the mode of binding and allowed initial optimization to be carried out using classical structure based design.

The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

A series of novel metal-organic in-plane complexes trans[Ru(NH3)4(LA)(LD)](PF6)3 (LA an acceptor substituted pyridineligand, LD an N-donor ligand) have been investigated using the hyper-Rayleigh scattering technique. Like other in-planecomplexes reported recently they exhibit very large and tunable static first hyperpolarizabilities (10 - 410 x iO° esu) which are associated with intense visible metal-to-ligand charge-transfer excitations. Moreover, a good correlation was foundbetween the hyperpolarizabilities and the electrochemical properties of the complexes.Furthermore, the effect of the oxidation state of the metal upon the molecular optical nonlinearity has been investigated. Chemical oxidation of the metal is proven to be an excellent tool to reversibly switch the molecular first hyperpolarizabilities of the trans-substituted ruthenium(II) complexes.Keywords: hyper-Rayleigh scattering, nonlinear optics, hyperpolarizability, metal-organic compounds 1. INTRODUCTION The search for materials displaying nonlinear optical (NLO) properties is a continuously expanding domain due toits possible applications in future telecommunication technologies, optical information processing, and data storage.Although the attention has been focused mainly on organic and polymeric materials, the advent of in-plane organometalliccompounds, i.e. complexes with metal-to-ligand charge transfer (MLCT) in the plane of the organic it-system (Fig. 1),recently led to the development of organometallic materials that show optical nonlinearities which can compete with thoseof their pure organic counterparts (e.g. metal acetylide complexes,1 asymmetrically substituted metal porphyrins2 and metalschiff base complexes3). This is in contrast to the previously studied out-of-plane complexes, e.g. ferrocene derivatives,that display only moderate hyperpolarizabilities. Hence, the in-plane charge transfer is suggested to improve the NLOproperties of the complex due to the more effective coupling between metal centre and ligand.47

A series of new Ru(II) complex salts trans-[Ru(NH(3))(4)(L(1))(L(2))](PF(6))(n) [n = 2, L(1) = 4-acetylpyridine (4-acpy) and L(2) = 4-(dimethylamino)pyridine (dmap) (1), 4-(dimethylamino)benzonitrile (dmabn) (2), 4-picoline (4-pic) (3), or 1-methylimidazole (1-MeIm) (4); n = 3, L(1) = N-methyl-4,4'-bipyridinium (MeQ(+)) and L(2) = dmap (6), dmabn (7), 1-MeIm (8), 4-acpy (9), or phenothiazine (PTZ) (10); n = 2, L(1) = dmap and L(2) = 4-pyridinecarboxaldehyde (pyca) (12) or ethyl isonicotinate (isne) (13)] have been synthesized and fully characterized. These complexes display intense, visible metal-to-ligand charge-transfer (MLCT) absorptions which are highly solvatochromic. An X-ray crystal structure determination has been carried out for trans-[Ru(NH(3))(4)(MeQ(+))(PTZ)](PF(6))(3).Me(2)CO (10.Me(2)CO). This salt, empirical formula C(26)H(38)F(18)N(7)OP(3)RuS, crystallizes in the hexagonal system, space group P6(3), with a = b = 17.853(4) Å, c = 21.514(6) Å, and Z = 6. The MeQ(+) ligand adopts an almost planar conformation, with a torsion angle of 9.6 degrees between the two pyridyl rings. The dipolar cations exhibit a strong projected component along the z axis, but crystal twinning precludes second-harmonic generation. Measurements of the first hyperpolarizability beta by using the hyper-Rayleigh scattering technique at 1064 nm yield very large values in the range (232-621) x 10(-30) esu, the largest being for trans-[Ru(NH(3))(4)(MeQ(+))(dmabn)](PF(6))(3) (7). These beta values are resonance enhanced via the MLCT excitations. A correlation between beta and the MLCT absorption energy confirms that this excitation is the primary contributor to beta. The two-level model yields static hyperpolarizabilities beta(0) in the range (10-130) x 10(-30) esu, with trans-[Ru(NH(3))(4)(MeQ(+))(dmap)](PF(6))(3) (6) having the largest. The beta(0) values of the complexes of the bipyridyl ligand MeQ(+) are larger than those of their analogues containing monopyridyl ligands because of extended conjugation. beta(0) correlates with the MLCT energy only when the MLCT absorption is sufficiently far from the second harmonic at 532 nm.